Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients

2012 ◽  
Vol 36 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Hannah Barrow ◽  
Jonathan M. Rhodes ◽  
Lu-Gang Yu
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Simultaneous Determination ◽  
Galectin 3 ◽  
Colorectal Cancer Patients

scholarly journals Galectin-3 expression in colorectal cancer and its correlation with clinical pathological characteristics and prognosis

Open Medicine ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. 226-230 ◽  
Author(s):  
Liu Tao ◽  
Li Jin ◽  
Li Dechun ◽  
Yang Hongqiang ◽  
Kou Changhua ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Protein Expression ◽  
Cancer Patients ◽  
Biological Marker ◽  
Progression Free Survival ◽  
Survival Times ◽  
Expression Levels ◽  
Galectin 3 ◽  
Colorectal Cancer Patients ◽  
Cancer Tissues

AbstractObjectiveTo explore the expression levels of galectin-3 in colorectal cancer and the association between galectin-3 and its clinical pathological parameters, as well as the prognosis of colorectal cancer patients.MethodsAn immunohistochemistry assay was used to test the expression levels of galectin-3 in cancer tissues of 61 colorectal cancer cases and in normal intestinal tissues adjacent to the cancer tissues of 23 cases. The associations between protein expression levels of galectin-3 and the clinicopathological features, such as age, sex, pathology type, lymphatic metastasis, and prognosis were also analyzed.ResultsThe positive rate of galectin-3 in cancer tissues was significantly higher than that of cancer-adjacent tissues: 62.5% (38/61) versus 13.0% (3/23) (P<0.05), respectively. Correlation was found between the protein expression of galectin-3 and the tumor size (P<0.05), as well as between the tumor differentiation (P<0.05) and Duke staging (P<0.05). The median progression-free survival times of patients with galectin-3 positive and negative expression were 19.2 and 35.1 months, respectively, with significant statistical difference (P<0.05).ConclusionGalectin-3 expression was correlated with the genesis and development of colorectal cancer and which could be used a biological marker for the prognosis of colorectal cancer patients.

Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients

2010 ◽  
Vol 32 (1) ◽  
pp. 160-164 ◽  
Author(s):  
Palma A. Iacovazzi ◽  
Maria Notarnicola ◽  
Maria G. Caruso ◽  
Vito Guerra ◽  
Silvia Frisullo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Galectin 3 ◽  
Colorectal Cancer Patients

scholarly journals Multiplex determination of serological signatures in the sera of colorectal cancer patients using hydrogel biochips

2016 ◽  
Vol 5 (7) ◽  
pp. 1361-1372 ◽  
Author(s):  
Veronika I. Butvilovskaya ◽  
Sofya B. Popletaeva ◽  
Vladimir R. Chechetkin ◽  
Zhanna I. Zubtsova ◽  
Marya V. Tsybulskaya ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

scholarly journals Circulating Galectin-1 and 90K/Mac-2BP Correlated with the Tumor Stages of Patients with Colorectal Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Keng-Liang Wu ◽  
Hong-Hwa Chen ◽  
Chen-Tzi Pen ◽  
Wen-Ling Yeh ◽  
Eng-Yen Huang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Enzyme Linked Immunosorbent Assay ◽  
Node Metastasis ◽  
Tumor Stages ◽  
Galectin 3 ◽  
Colorectal Cancer Patients

Background. The simultaneous correlation of serum galectin-1, galectin-3, and 90K/Mac-2BP levels with clinical stages of patients with colorectal cancer has not yet been clarified. We plan to measure the serum levels of galectin-1, galectin-3, and 90K/Mac-2BP of patients at different stages of colorectal cancer and analyze the correlation of these galectins with stages of colorectal cancers.Methods. 198 colorectal cancer patients (62 ± 13 (range 31–85) years old, 43.6% female) were recruited for this study. Subjects’ blood samples were checked for serum galectin-1, galectin-3, 90K/Mac-2BP, and carcinoembryonic antigen by sandwich enzyme-linked immunosorbent assay. We determined the correlation between plasma concentrations with clinical tumor stages.Results. Colorectal cancer patients with larger cancer sizes (stages T3, T4 rather than T1, T2) have higher serum 90K/Mac-2BP (P= 0.014) and patients with lymph node metastasis have higher serum galectin-1 (P= 0.002) but there was not a significant correlation between galectin-3 and tumor staging of colon cancer. In colorectal cancer patients even with normal carcinoembryonic antigen, serum galectin-1 could predict more lymph node metastasis.Conclusions. We found 90K/Mac-2BP correlated with the size of colorectal cancer. Galectin-1 but not galectin-3 was associated with lymph node metastasis. Galectin-1 could predict more lymph node metastasis in colorectal cancer patients with normal serum carcinoembryonic antigen.

Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients

2009 ◽  
Vol 00 (00) ◽  
pp. 090818045952033-5 ◽  
Author(s):  
Palma A. Iacovazzi ◽  
Maria Notarnicola ◽  
Maria G. Caruso ◽  
Vito Guerra ◽  
Silvia Frisullo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Galectin 3 ◽  
Colorectal Cancer Patients

Determination of splice-site mutations in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay

2009 ◽  
Vol 8 (4) ◽  
pp. 509-517 ◽  
Author(s):  
Hiromu Naruse ◽  
Noriko Ikawa ◽  
Kiyoshi Yamaguchi ◽  
Yusuke Nakamura ◽  
Masami Arai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lynch Syndrome ◽  
Cancer Patients ◽  
Splice Site ◽  
Colorectal Cancer Patients

scholarly journals DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients

2018 ◽  
Vol 8 (4) ◽  
pp. 45 ◽  
Author(s):  
Arsalan Amirfallah ◽  
Gizem Kocal ◽  
Olcun Unal ◽  
Hulya Ellidokuz ◽  
Ilhan Oztop ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Methylenetetrahydrofolate Reductase ◽  
Dihydropyrimidine Dehydrogenase ◽  
Predictive Biomarkers ◽  
Related Factors ◽  
Mthfr Polymorphisms ◽  
Hematopoietic Toxicity ◽  
Colorectal Cancer Patients

Fluoropyrimidine-based chemotherapy is extensively used for the treatment of solid cancers, including colorectal cancer. However, fluoropyrimidine-driven toxicities are a major problem in the management of the disease. The grade and type of the toxicities depend on demographic factors, but substantial inter-individual variation in fluoropyrimidine-related toxicity is partly explained by genetic factors. The aim of this study was to investigate the effect of dihydropyrimidine dehydrogenase (DPYD), thymidylate synthase (TYMS), and methylenetetrahydrofolate reductase (MTHFR) polymorphisms in colorectal cancer patients. Eighty-five patients who were administered fluoropyrimidine-based treatment were included in the study. The DPYD, TYMS and MTHFR polymorphisms were scanned by a next generation Sequenom MassARRAY. Fluoropyrimidine toxicities were observed in 92% of all patients. The following polymorphisms were detected: DPYD 85T>C (29.4% heterozygote mutants, 7.1% homozygote mutants), DPYD IVS 14+1G>A (1.2% heterozygote mutants), TYMS 1494del TTAAAG (38.4% heterozygote mutants, 24.7% homozygote mutants), MTHFR 677C>T (43.5% heterozygote mutants, 9.4% homozygote mutants) and MTHFR 1298A>C (8.2% heterozygote mutants, 2.4% homozygote mutants). A statistically significant association was demonstrated between MTHFR 677C>T and fluoropyrimidine-related toxicity. Furthermore, MTHFR 1298A>C was associated with hematopoietic toxicity. MTHFR polymorphisms may be considered as related factors of fluoropyrimidine toxicity and may be useful as predictive biomarkers for the determination of the colorectal cancer patients who can receive the greatest benefit from fluoropyrimidine-based treatments.

Sign in / Sign up

Export Citation Format

Share Document